Adding Interventional DED Treatment to Your Practice - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Adding Interventional DED Treatment to Your Practice

Interventional treatment for DED before refractive surgery biometry allows practices to offer options like advanced-technology intraocular lenses to more patients.

  • By

  • Neel R. Desai, MD

  • January 1, 2026

  • 14 min

Share

Clinical Scorecard: Adding Interventional DED Treatment to Your Practice

At a Glance

CategoryDetail
Condition
Key MechanismsInterventional treatments including lacrimal occlusion, thermal-activated restorative gland expression therapy, and intense pulsed light, supported by clinical studies.
Target Population
Care Setting

Key Highlights

  • Clarify that TARGET therapy is specifically for meibomian gland dysfunction and provide comparative data.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • Evaluate patient response using specific metrics such as symptom questionnaires and visual acuity.

      Risks

        Patient & Prescribing Data

        Interventional treatments can lead to immediate symptom relief and improved compliance with conventional therapies, including specific examples.

        Clinical Best Practices

        • Implement structured patient education sessions that detail the benefits and usage of interventional therapies.

        Related Resources & Content

        Original Source(s)

        Adding Interventional DED Treatment to Your Practice

        • by Neel R. Desai, MD

        • January 1, 2026

        Related Content

        Incomplete rather than complete nasolacrimal duct obstruction Is strongly associated with meibomian gland dysfunction in postmenopausal women with PANDO: a cross-sectional study

        Cracking the Code: Which Ocular Symptoms Predict Dry Eye Signs? Insights From a Large International Sicca Registry

        Scleral Lens Evolution

        This article will examine the indications, clinical evidence, and practical considerations for managing severe ocular surface disease and inflammatory dry eye using scleral lenses, and offer guidance to practitioners who seek to expand their therapeutic options.